Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study

Berthold, Dominik R.; Pond, Greg; Dewit, R; Eisenberger, Mario; Tannock, I. F.

doi:10.1200/jco.2007.25.18_suppl.5005

Cited by 104 publications

(129 citation statements)

References 0 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Additional hormone manipulations such as antiandrogen withdrawal, complete androgen blockade and the use of oestrogen–progesterone derivatives have been employed with conflicting results [5,6]. The presence of unfavourable conditions such as the onset of tumour‐related symptoms or of progressive bone or parenchyma metastases justifies the resort to a docetaxel‐based chemotherapy for cytoreduction [7–9]. It must be emphasized that sometimes elderly patients who are unfit because of concomitant diseases are not suitable for chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

Procopio¹,

Guadalupi²,

Giganti³

et al. 2010

BJU International

View full text Add to dashboard Cite

Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Ketoconazole is an inhibitor of adrenal androgen synthesis which carries on the anti‐tumour activity by interfering with different enzymes, cytochrome P450 14‐α‐demethylase, C 17,20 lyase and C 17 α‐hydroxylase. Some studies have shown an anti‐tumour activity of ketoconazole employed at different dose levels following the failure of androgen‐suppressive therapies. Patients refractory to pharmacological castration and/or chemotherapy could have an additional benefit in terms of disease control from the use of low dose of ketoconazole. The safety profile was good. OBJECTIVE To assess the efficacy of ketoconazole in patients with castration‐resistant prostate cancer (CRPC). PATIENTS AND METHODS From April 2008 to November 2009, 37 patients with CRPC have been treated with ketoconazole. The primary endpoint was the prostate‐specific antigen (PSA) response; the secondary endpoints were progression‐free survival and safety profile. Ketoconazole was administered by oral route at a dose of 200 mg every 8 h continuous dosing until the onset of serious adverse events or disease progression. The study was based on a two‐step design with an interim efficacy analysis carried out on the first 12 patients accrued. RESULTS Main characteristics of population were: median age 75 years (range 60–88); baseline mean PSA 28.8 ng/mL (4.3–1000); 30 patients previously challenged with at least two lines of hormone therapy; 15 patients previously treated with chemotherapy. Biochemical responses accounted for: two complete responses (5%), six partial responses (16%), 13 patients with stable disease (35%), and 14 with progressive disease (38%). Of 15 patients resistant to chemotherapy, overall disease control (complete plus partial responses plus stable disease) was recorded in seven of them. Treatment was feasible without inducing grade 3–4 adverse events. The most common grade 1–2 adverse events were asthenia (27%), vomiting (8%) and abdominal pain (8%). CONCLUSION Treatment with low‐dose ketoconazole is feasible and well tolerated. The efficacy was satisfactory in patients previously treated with chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

Procopio¹,

Guadalupi²,

Giganti³

et al. 2010

BJU International

View full text Add to dashboard Cite

show abstract

“…In an extended survival analysis of the TAX 327 study , in which patients with symptomatic mCRPC or evident disease progression were included, docetaxel could bring about significantly longer median OS (19.2 months) in patients when compared with mitoxantrone (16.3 months). The OS advantage of docetaxel was also consistent across varied patient subgroups.…”

Section: Resultsmentioning

confidence: 99%

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology

Poon

Chan

et al. 2018

BJU International

View full text Add to dashboard Cite

To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate. At the final meeting, each drafted statement was voted on by every member based on its practicability of recommendation in the locality. After the panel voting, a total of 45 consensus statements regarding the management of mPCa were ultimately accepted and established. The consensus statements were primarily derived from the latest clinical evidence and major overseas guidelines, with the consideration of local clinical experience and practicability. These are considered applicable recommendations for Hong Kong physicians for the management of mPCa patients.

show abstract

“…This study demonstrated improved survival in patients treated with the 3‐weekly docetaxel and prednisone regimen compared to the mitoxantrone and prednisone arm. In the most recent update 8 the survival benefit of 3‐weekly docetaxel has been shown to persist (median survival 19.2 vs 17.8 vs 16.3 months for 3‐weekly docetaxel, weekly docetaxel and mitoxantrone respectively, P = 0.004). The corresponding 3‐year survival rate was 17.9, 16.7 and 13.7%, respectively.…”

Section: First‐line Chemotherapymentioning

confidence: 99%

Second‐line therapy for castrate‐resistant prostate cancer: A literature review

Kao

Hovey

Marx

2011

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Despite a survival benefit in the first-line treatment of castrate-resistant prostate cancer (CRPC) with docetaxel, the prognosis remains limited. There are increasing options available for patients with CRPC in the second-line setting, but there is currently little consensus regarding the optimal treatment. There have been numerous phase II and retrospective studies examining second-line options in CRPC, including retreatment with docetaxel, mitoxantrone, cyclophosphamide and carboplatin, which can be associated with meaningful responses in a significant minority of patients. In 2010 three randomized trials were published or presented which demonstrated a survival benefit in the second-line setting. These included cabazitaxel compared with mitoxantrone, sipuleucel-T (immunotherapy) and abiraterone acetate versus placebo. Ongoing research in the second-line setting of CRPC to optimize treatment options, with the objectives of survival prolongation, improvement in quality of life and pain management, is still needed.

show abstract

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study

Cited by 104 publications

References 0 publications

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology

Second‐line therapy for castrate‐resistant prostate cancer: A literature review

Contact Info

Product

Resources

About